Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A multi-site, interventional, non-comparative, single-arm trial to evaluate the safety of the Keeogo™ Dermoskeleton in subjects with hemiparesis due to ischemic or hemorrhagic stroke.
Stroke affects thousands of individuals annually, leading to considerable physical impairment and functional disability. Gait is one of the most important activities of daily living affected in this patient population. Recent technological developments in passively powered dermoskeleton can create powerful adjunctive tools for rehabilitation and potentially accelerate functional recovery. Here, the investigators present the development and evaluation of a lower limb dermoskeleton, namely Keeogo™ (B-Temia), for use in rehabilitation institutions to assist individuals with hemiparesis due to stroke who are able to stand and initiate a step in performing ambulatory functions.
Keeogo™ Dermoskeleton is a low-profile, assistive exoskeleton (or 'dermoskeleton') that orthotically fits to the lower limbs. Keeogo™ is worn on the user's lower body using a belt and contact areas attached around the thighs and calves.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Keeogo™ Dermoskeleton | Experimental | Keeogo™ Dermoskeleton is a low-profile, assistive exoskeleton (or 'dermoskeleton') that orthotically fits to the lower limbs. Keeogo™ is worn on the user's lower body using a belt and contact areas attached around the thighs and calves. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Keeogo™ Dermoskeleton | Device | This device is intended for use in rehabilitation institutions to assist individuals with hemiparesis due to stroke who are able to stand and initiate a step in performing ambulatory functions. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of device-related adverse events [Safety] | Safety will be evaluated on the basis of the number of device-related serious adverse events reported for subjects during their participation in the study. | Duration of study participation for each subject, estimated 3-5 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of device malfunctions during study procedures [Device Reliability] | Device reliability will be evaluated on the basis of the number of device malfunctions reported by research study staff for the duration of study procedures at each study site. | Duration of study completion for each site, estimated 3-5 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| 30-Second Chair Stand Test | Subjects sit in the middle of chair and place hands on opposite shoulder crossed at wrists. Keeping feet flat on floor, back straight, arms against chest, subjects rise to full standing position when told "go" followed by sit down, the start position. This movement is repeated for as many times as possible for 30 seconds. Additionally, the test is repeated for a total of 5 cycles with short rest (≤ 90 seconds) between sets. Patient and Clinician reported outcomes are assessed for this measure via a sit-to-stand-to-sit question on the survey given for the secondary effectiveness endpoint. |
Inclusion Criteria:
To be eligible to participate in this study, an individual must meet all of the following criteria:
Provide signed and dated informed consent form;
Willing to comply with all study procedures and be available for the duration of the study [2-3 days per week, 3-5 consecutive weeks];
Adults 18 years of age and older;
Confirmed Cerebrovascular Accident (CVA) with hemiparesis;
Stable stroke (≥ 6 months post-incident)
Sufficient cognition to follow simple instructions and understand the content and purpose of the study (MMSE > 20);
Capable of standing and walking independently for an extended period of time (MMT
Presence of any gait deficit, as defined by one or more of the following clinical observations:
Manual Muscle Test (MMT) of 4/5 for the unaffected upper extremity;
Able to sit on a bench for more than 5 minutes;
Is physically and mentally compatible with device to demonstrate ability to safely activate the Keeogo™ user interface;
Able to understand and follow instructions with assistance if needed.
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Arun Jayaraman, PT, PhD. | Shirley Ryan Ability Lab (SRA) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Shirley Ryan Ability Lab (SRA) | Chicago | Illinois | 60611 | United States | ||
| Human Performance and Engineering Research (HPER) |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26289955 | Background | Buesing C, Fisch G, O'Donnell M, Shahidi I, Thomas L, Mummidisetty CK, Williams KJ, Takahashi H, Rymer WZ, Jayaraman A. Effects of a wearable exoskeleton stride management assist system (SMA(R)) on spatiotemporal gait characteristics in individuals after stroke: a randomized controlled trial. J Neuroeng Rehabil. 2015 Aug 20;12:69. doi: 10.1186/s12984-015-0062-0. | |
| 30248015 |
| Label | URL |
|---|---|
| Disability and Functioning (Noninstitutionalized Adults Aged 18 and Over) | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Device: Keeogo™ Dermoskeleton This device is intended for use in rehabilitation institutions to assist individuals with hemiparesis due to stroke who are able to stand and initiate a step in performing ambulatory functions.
Not provided
Not provided
Sites will enroll participants in order of recruitment. No other randomization procedure will be applied.
Not provided
| Incidence of injury to Physical Therapist (PT) caused by device [PT safety] |
PT safety will be evaluated on the basis of the number of serious device-related injuries reported by study physical therapists for the duration of study procedures at each study site. |
| Duration of study completion for each site, estimated 3-5 weeks |
| Device, Effectiveness | Clinician and Patient Reported Outcomes (surveys) will be used to assess the effectiveness of the device in assisting gait. The surveys will rate subject performance in walking based on clinician observed deviations and subject perception of mobility limitation due to the stroke.
| Duration of study participation for each subject, estimated 3-5 weeks |
| Duration of study completion for each site, estimated 3-5 weeks |
| Timed Stair Test | Subjects start with both feet on the bottom landing then ascend and descend a set number of stairs as quickly as possible in a safe manner using a rail only if needed. Time is recorded from ascent through descent. Patient and Clinician reported outcomes are assessed for this measure via a stair ascent/descent question on the survey given for the secondary effectiveness endpoint. | Duration of study completion for each site, estimated 3-5 weeks |
| Patient and Clinician Reported Outcomes (surveys) | Questionnaires provide patient and clinician-centric view of treatment of gait deficit. | Duration of study completion for each site, estimated 3-5 weeks |
| West Orange |
| New Jersey |
| 07052 |
| United States |
| James J Peters VA Medical Center - Center for the Medical Consequences of Spinal Cord Injury | The Bronx | New York | 10468 | United States |
| Assistive Technology Clinic (ATC) | Toronto | Ontario | M6A 2E1 | Canada |
| Xu J, Murphy SL, Kochanek KD, Bastian B, Arias E. Deaths: Final Data for 2016. Natl Vital Stat Rep. 2018 Jul;67(5):1-76. |
| 28533700 | Background | He Y, Eguren D, Luu TP, Contreras-Vidal JL. Risk management and regulations for lower limb medical exoskeletons: a review. Med Devices (Auckl). 2017 May 9;10:89-107. doi: 10.2147/MDER.S107134. eCollection 2017. |
| 29183379 | Background | Lee SH, Lee HJ, Chang WH, Choi BO, Lee J, Kim J, Ryu GH, Kim YH. Gait performance and foot pressure distribution during wearable robot-assisted gait in elderly adults. J Neuroeng Rehabil. 2017 Nov 28;14(1):123. doi: 10.1186/s12984-017-0333-z. |
| 23850614 | Background | Morawietz C, Moffat F. Effects of locomotor training after incomplete spinal cord injury: a systematic review. Arch Phys Med Rehabil. 2013 Nov;94(11):2297-308. doi: 10.1016/j.apmr.2013.06.023. Epub 2013 Jul 9. |
| Mapping Connections. An Understanding of Neurological Conditions in Canada. The National Population Health Study of Neurological Conditions.: Neurological Health Charities Canada. Government of Canada. Canadian Institutes of Health Research. | View source |
| Canada S. Canada at a Glance 2018. Population | View source |
| Medical Devices; Physical Medicine Devices; Classification of the Powered Exoskeleton A Rule by the Food and Drug Administration on 02/24/2015 | View source |
| (CDC) CfDCaP. National Center for Health Statistics - Cerebrovascular Disease or Stroke | View source |
| ID | Term |
|---|---|
| D000083242 | Ischemic Stroke |
| D000083302 | Hemorrhagic Stroke |
| D020521 | Stroke |
| D010291 | Paresis |
| ID | Term |
|---|---|
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided